查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1375981

特发性血小板减少紫斑症治疗药物市场规模、份额、趋势分析报告：依疾病类型、地区、细分市场预测，2023-2030年

Idiopathic Thrombocytopenic Purpura Therapeutics Market Size, Share & Trends Analysis Report By Disease Type (Corticosteroids, IVIG, Anti-D Immunoglobulins, TPO-RA, Others), By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 60 Pages | 商品交期: 2-10个工作天内

价格

特发性血小板减少紫斑症治疗药物市场成长与趋势：

Grand View Research, Inc.最新报告显示，到2030年，全球特发性血小板减少紫斑症药物市场将达到9.149亿美元，2023年至2030年年复合成长率为5.0%，预计。

随着 IVIG 和 TPO-RA 类新药的推出，研究和开发的增加预计将推动预测期内的成长。此外，旨在鼓励新产品开发的美国孤儿药法案等政府法规预计将推动成长。

业界对联合治疗联合治疗的需求正在增加，因为与其他治疗方法相比，联合疗法显示出更高的效率。此外，它具有成本效益，有助于限制与个别治疗层级相关的副作用。主要联合治疗包括地塞米松和利妥昔单抗、地塞米松和TPO-RA、IVIG和皮质类固醇。脾切除术（切除脾臟的手术）旨在减少抗血小板抗体​​的数量，预计将推动需求。皮质类固醇通常用于治疗特发性血小板减少紫斑症。皮质类固醇的使用率非常高，被认为是治疗ITP患者的第一线药物。

特发性血小板减少紫斑症治疗市场报告亮点

  • 由于给药艾曲波帕和罗米司亭治疗的患者的高反应率，TPO-RA 预计将出现显着增长，从 2023 年到 2030 年，年复合成长率将超过 6.6%。此外，随着2015年Avatrombopag的商业化，对TPO-RA的需求预计将增加。此外，TPO-RA 治疗脾切除患者復发的能力预计将推动未来年度的需求。
  • 北美市场占据主导地位，2022 年销售份额最大，为 39.9%。
  • 预计亚太地区在预测期内将以 6.2% 的最快年复合成长率成长。
  • 由于积极的政府配合措施以及澳洲和日本先进的医疗基础设施，亚太地区预计在未来年度将显着成长。此外，中国和印度等新兴市场预计将推动成长，因为有许多开拓的机会。

目录

第1章调查方法和范围

第2章执行摘要

第3章特发性血小板减少紫斑症治疗药物市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 普及和成长前景图
  • 市场动态
    • 市场驱动因素分析
    • 市场抑制因素分析
  • 特发性血小板减少紫斑症治疗药物市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第4章特发性血小板减少紫斑症治疗药物市场：疾病类型估计与趋势分析

  • 特发性血小板减少紫斑症治疗药物市场，依疾病类型分類的要点
  • 特发性血小板减少紫斑症治疗药物市场：2022 年和 2030 年趋势和市场占有率分析
  • 急性ITP
  • 慢性的
  • 其他的

第5章特发性血小板减少紫斑症治疗药物市场：产品估算与趋势分析

  • 特发性血小板减少紫斑症治疗药物市场，依产品分類的要点
  • 特发性血小板减少紫斑症治疗药物市场：2022 年和 2030 年趋势和市场占有率分析
  • 皮质类固醇
  • IVIG
  • 抗D免疫球蛋白
  • TPO-RA
  • 其他的

第6章特发性血小板减少紫斑症治疗药物市场：区域估计与趋势分析

  • 区域展望
  • 按地区分類的特发性血小板减少紫斑症治疗药物市场：主要市场点
  • 北美洲
    • 2018-2030 年市场估计与预测
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 瑞典
    • 挪威
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 泰国
    • 韩国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东/非洲
    • 沙乌地阿拉伯
    • 南非
    • 阿拉伯聯合大公国
    • 科威特

第7章竞争形势

  • 主要市场参与企业的最新趋势和影响分析
  • 公司/竞争分类
    • Amgen Inc.
    • F. Hoffmann-La Roche Ltd
    • Grifols, SA
    • GSK plc.
    • Shangxian Minimal Invassive Inc.
    • INTROMEDIC
    • Medtronic
    • FUJIFILM Holdings Corporation
    • Olympus Corporation
    • JINSHAN Science & Technology (Group) Co., Ltd.
Product Code: 978-1-68038-289-1

Idiopathic Thrombocytopenic Purpura Therapeutics Market Growth & Trends:

The global idiopathic thrombocytopenic purpura therapeutics market is expected to reach USD 914.9 million by 2030, expanding at a CAGR of 5.0% from 2023 to 2030, according to a new report by Grand View Research, Inc.. Rising R&D leading to the introduction of new drugs for IVIG and TPO-RA classes is expected to propel growth over the forecast period. In addition, government regulation such as the Orphan Drug Act in the United States with an aim to encourage new product development is projected to fuel growth.

The industry is characterized by a rising demand for combination therapies as they exhibit higher efficiency as compared to other treatments. Moreover, they are cost-efficient and help curb side effects associated with individual therapeutic classes. Some of the major combination therapies are dexamethasone and rituximab, dexamethasone and TPO-RA, IVIG, and corticosteroids. Splenectomy, the procedure to remove the spleen is aimed at reducing the amount of anti-platelet antibodies, is expected to fuel demand. Corticosteroids are regularly used in idiopathic thrombocytopenic purpura treatment. Since corticosteroid are considered to be the first line of therapy for patients suffering from ITP, the usage rates of corticosteroid are very high.

Idiopathic Thrombocytopenic Purpura Therapeutics Market Report Highlights:

  • TPO-RA is likely to witness substantial growth, growing at a CAGR of over 6.6% from 2023 to 2030 owing to high response rates exhibited by patients administered with Eltrombopag and Romiplostim. Moreover, demand for TPO-RA is expected to increase due to the commercialization of Avatrombopag in 2015. In addition, the ability of TPO-RA to cater to splenectomized patients witnessing relapses is expected fuel demand over the next six years.
  • North America dominated the market and accounted for the largest revenue share of 39.9% in 2022.
  • Asia Pacific is expected to grow at the fastest CAGR of 6.2% over the forecast period.
  • Asia Pacific is expected to experience substantial growth over the next six years, owing to the presence of favorable government initiatives, and sophisticated healthcare infrastructure in Australia and Japan. In addition, the presence of vast untapped opportunities in emerging markets such as China and India is expected to propel growth.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Disease Type
    • 1.1.2. Product
    • 1.1.3. Regional scope
    • 1.1.4. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives
    • 1.9.1. Objective 1
    • 1.9.2. Objective 2

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Disease type outlook
    • 2.2.2. Product outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Idiopathic Thrombocytopenic Purpura Therapeutics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
  • 3.4. Idiopathic Thrombocytopenic Purpura Therapeutics Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic landscape

Chapter 4. Idiopathic Thrombocytopenic Purpura Therapeutics Market: Disease Type Estimates & Trend Analysis

  • 4.1. Idiopathic Thrombocytopenic Purpura Therapeutics Market, By Disease Type Key Takeaways
  • 4.2. Idiopathic Thrombocytopenic Purpura Therapeutics Market: Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Acute ITP
    • 4.3.1. Acute ITP market estimates and forecasts, 2018 to 2030, (USD Million)
  • 4.4. Chronic
    • 4.4.1. Chronic market estimates and forecasts, 2018 to 2030, (USD Million)
  • 4.5. Others
    • 4.5.1. Others market estimates and forecasts, 2018 to 2030, (USD Million)

Chapter 5. Idiopathic Thrombocytopenic Purpura Therapeutics Market: Product Estimates & Trend Analysis

  • 5.1. Idiopathic Thrombocytopenic Purpura Therapeutics Market, By Product Key Takeaways
  • 5.2. Idiopathic Thrombocytopenic Purpura Therapeutics Market: Movement & Market Share Analysis, 2022 & 2030
  • 5.3. Corticosteroids
    • 5.3.1. Corticosteroids market estimates and forecasts, 2018 to 2030, (USD Million)
  • 5.4. IVIG
    • 5.4.1. IVIG market estimates and forecasts, 2018 to 2030, (USD Million)
  • 5.5. Anti-D Immunoglobulins
    • 5.5.1. Anti-D Immunoglobulins market estimates and forecasts, 2018 to 2030, (USD Million)
  • 5.6. TPO-RA
    • 5.6.1. TPO-RA market estimates and forecasts, 2018 to 2030, (USD Million)
  • 5.7. Others
    • 5.7.1. Others market estimates and forecasts, 2018 to 2030, (USD Million)

Chapter 6. Idiopathic Thrombocytopenic Purpura Therapeutics Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Outlook
  • 6.2. Idiopathic Thrombocytopenic Purpura Therapeutics Market by Region: Key Marketplace Takeaway
  • 6.3. North America
    • 6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.2. U.S.
      • 6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.3. Canada
      • 6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4. Europe
    • 6.4.1. U.K.
      • 6.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.2. Germany
      • 6.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.3. France
      • 6.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.4. Italy
      • 6.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.5. Spain
      • 6.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.6. Sweden
      • 6.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.7. Norway
      • 6.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.8. Denmark
      • 6.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.2. China
      • 6.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.3. India
      • 6.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.4. Australia
      • 6.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.5. Thailand
      • 6.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.6. South Korea
      • 6.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.6. Latin America
    • 6.6.1. Brazil
      • 6.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.2. Mexico
      • 6.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.3. Argentina
      • 6.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.7. MEA
    • 6.7.1. Saudi Arabia
      • 6.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.2. South Africa
      • 6.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.3. UAE
      • 6.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.4. Kuwait
      • 6.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
    • 7.2.1. Amgen Inc.
      • 7.2.1.1. Company overview
      • 7.2.1.2. Financial performance
      • 7.2.1.3. Disease Type benchmarking
      • 7.2.1.4. Strategic initiatives
    • 7.2.2. F. Hoffmann-La Roche Ltd
      • 7.2.2.1. Company overview
      • 7.2.2.2. Financial performance
      • 7.2.2.3. Disease Type benchmarking
      • 7.2.2.4. Strategic initiatives
    • 7.2.3. Grifols, S.A.
      • 7.2.3.1. Company overview
      • 7.2.3.2. Financial performance
      • 7.2.3.3. Disease Type benchmarking
      • 7.2.3.4. Strategic initiatives
    • 7.2.4. GSK plc.
      • 7.2.4.1. Company overview
      • 7.2.4.2. Financial performance
      • 7.2.4.3. Disease Type benchmarking
      • 7.2.4.4. Strategic initiatives
    • 7.2.5. Shangxian Minimal Invassive Inc.
      • 7.2.5.1. Company overview
      • 7.2.5.2. Financial performance
      • 7.2.5.3. Disease Type benchmarking
      • 7.2.5.4. Strategic initiatives
    • 7.2.6. INTROMEDIC
      • 7.2.6.1. Company overview
      • 7.2.6.2. Financial performance
      • 7.2.6.3. Disease Type benchmarking
      • 7.2.6.4. Strategic initiatives
    • 7.2.7. Medtronic
      • 7.2.7.1. Company overview
      • 7.2.7.2. Financial performance
      • 7.2.7.3. Disease Type benchmarking
      • 7.2.7.4. Strategic initiatives
    • 7.2.8. FUJIFILM Holdings Corporation
      • 7.2.8.1. Company overview
      • 7.2.8.2. Financial performance
      • 7.2.8.3. Disease Type benchmarking
      • 7.2.8.4. Strategic initiatives
    • 7.2.9. Olympus Corporation
      • 7.2.9.1. Company overview
      • 7.2.9.2. Financial performance
      • 7.2.9.3. Disease Type benchmarking
      • 7.2.9.4. Strategic initiatives
    • 7.2.10. JINSHAN Science & Technology (Group) Co., Ltd.
      • 7.2.10.1. Company overview
      • 7.2.10.2. Financial performance
      • 7.2.10.3. Disease Type benchmarking
      • 7.2.10.4. Strategic initiatives

List of Tables

  • Table 1 List of Abbreviation
  • Table 2 North America idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 3 North America idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 4 North America idiopathic thrombocytopenic purpura therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 5 U.S. idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 6 U.S. idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 7 Canada idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 8 Canada idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 9 Europe idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 10 Europe idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 11 Europe idiopathic thrombocytopenic purpura therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 12 Germany idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 13 Germany idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 14 UK idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 15 UK idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 16 France idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 17 France idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 18 Italy idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 19 Italy idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 20 Spain idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 21 Spain idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 22 Denmark idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 23 Denmark idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 24 Sweden idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 25 Sweden idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 26 Norway idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 27 Norway idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 28 Asia Pacific idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 29 Asia Pacific idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific idiopathic thrombocytopenic purpura therapeutics market, by country, (USD Million) 2018 - 2030
  • Table 31 Japan idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 32 Japan idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 33 China idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 34 China idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 35 India idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 36 India idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 37 Thailand idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 38 Thailand idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 39 South Korea idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 40 South Korea idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 41 Latin America idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 42 Latin America idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 43 Latin America idiopathic thrombocytopenic purpura therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 44 Brazil idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 45 Brazil idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 46 Mexico idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 47 Mexico idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 48 Argentina idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 49 Argentina idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 50 Middle East and Africa idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 51 Middle East and Africa idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 52 Middle East and Africa idiopathic thrombocytopenic purpura therapeutics market, by country, (USD Million) 2018 - 2030
  • Table 53 Saudi Arabia idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 54 Saudi Arabia idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 55 South Africa idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 56 South Africa idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 57 UAE idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 58 UAE idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 59 Kuwait idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 60 Kuwait idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Idiopathic thrombocytopenic purpura therapeutics: market outlook
  • Fig. 9 Idiopathic thrombocytopenic purpura therapeutics competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Idiopathic thrombocytopenic purpura therapeutics market driver impact
  • Fig. 15 Idiopathic thrombocytopenic purpura therapeutics market restraint impact
  • Fig. 16 Idiopathic thrombocytopenic purpura therapeutics market strategic initiatives analysis
  • Fig. 17 Idiopathic thrombocytopenic purpura therapeutics market: Disease type movement analysis
  • Fig. 18 Idiopathic thrombocytopenic purpura therapeutics market: Disease type outlook and key takeaways
  • Fig. 19 Acute ITP market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Chronic market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Idiopathic thrombocytopenic purpura therapeutics market: Product type movement analysis
  • Fig. 23 Idiopathic thrombocytopenic purpura therapeutics market: Product type outlook and key takeaways
  • Fig. 24 OGIB market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 IVIG market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Anti-D immunoglobulins market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 TPO-RA market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Global idiopathic thrombocytopenic purpura therapeutics market: Regional movement analysis
  • Fig. 30 Global idiopathic thrombocytopenic purpura therapeutics market: Regional outlook and key takeaways
  • Fig. 31 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)